VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

American Journal of Hypertension

Volumn 16, Issue 7, 2003, Pages 544-548

  Julius, Stevo ^a,k   Kjeldsen, Sverre E ^b   Brunner, Hans ^c   Hansson, Lennart ^d   Platt, Francis ^e   Ekman, Steffan ^e   Laragh, John H ^f   McInnes, Gordon ^g   Schork, Anthony M ⁱ   Smith, Beverly ^e   Weber, Michael ^h   Zanchetti, Alberto ^j  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UPPSALA UNIVERSITY   (Sweden)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h Downstate Health Sciences University   (United States)

ⁱ UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

Amlodipine; Blood pressure response to drugs; Pulse pressure; Valsartan

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; STANDARD; SYSTOLIC BLOOD PRESSURE;

EID: 10744226529     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00904-X     Document Type: Article

References (18)

1. Mann J, Julius S, for the VALUE Trial Group: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7:176-183.
2. Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, Laragh J, McInnes G, Smith B, Weber M, Zanchetti A, for the VALUE Trial Group: Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Pressure 2001;10:83-91.
3. Joint National Committee: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
4. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P: Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-1102.
5. De Henaw S, De Bacquer D, Fonteyne W, Starn M, Kornitzer M, De Backer G: Trends in the prevalence, detection, treatment and control of arterial hypertension in the Belgian adult population. J Hypertens 1998;16:277-284.
6. Cifkova R, Skodova Z, Hejl Z, Adamkova V, Novozamska E, Pitha J, Jozifova M: Decreased prevalence and improved control of hypertension in the Czeck population (Abstract). Am J Hypertens 1999;12:95A.
7. Colhoun HM, Dong W, Poulter NR: Blood pressure screening, management and control in England: Results from the health survey for England 1994. J Hypertens 1998;16:747-752.
8. Coca Payeras A: Evolucion del control del la hipertension arterial en espana. Resultados del Estudio Controlpres 98 Hypertension 1998; 15:298-308.
9. Kastarinen MJ, Salomaa VV, Variainen EA, Jousilahti PJ, Tuomilehto JO, Puska PM, Nissinen AM: Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. J Hypertens 1998;16:1379-1387.
10. Hansson L, Lindholm LH, for the STOP-Hypertension-2 study group: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-1756.
11. Hansson L, Hedner T, for the NORDIL Study Group: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-365.
12. Staessen JA, Fagard R, Thijs L, Celis H: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
13. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck J-E, for the Captopril Prevention Project (CAPPP) study group: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-616.
14. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-3264.
15. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Hot Study Group. Lancet 1998;351:1755-1762.
16. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002;359:996-1003.
17. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-372.
18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.